×
Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Human Vaccines Market Size

ID: MRFR/Pharma/1984-HCR
200 Pages
Rahul Gotadki
February 2026

Human Vaccines Market Research Report By Vaccine Type (Inactivated, Live Attenuated, Subunit, Recombinant, Toxoid), By Application (Preventive Vaccines, Therapeutic Vaccines, Travel Vaccines, Influenza Vaccines), By Administration Route (Intramuscular, Subcutaneous, Oral, Intradermal), By Target Diseases (Infectious Diseases, Oncological Diseases, Autoimmune Diseases) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) -Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Human Vaccines Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Human Vaccines Size

Human Vaccines Market Growth Projections and Opportunities

The human vaccines market is impacted by many factors that in combination define its development, which reflects ongoing changes in the incidence of contagious diseases and intervening technologies on a global scale. One of the main catalysts for the human vaccines market is global focus on disease prevention via immunization programs. Nevertheless governments, international organizations and public health agencies operate together on vaccination programs that address several infectious diseases stimulating further demand for the vaccine. Recent pandemics such as COVID-19 have made pandemic preparedness one of the hottest topics in global health. This has led to increased investment in vaccine research, development and production capacities leading inevitably to an increased demand for vaccines against these new viral perils. The market has been profoundly influenced by the constant development of vaccine technology. Revolutionary breakthroughs in mRNA, viral vector and recombinant DNA technologies have opened the path for development of novel innovative vaccines with improved efficacy, safety profiles as well rapid production which serve to benefit growth prospects. The growing campaigns to widen immunization coverage worldwide, particularly in low- and middle-income countries contributes into the development of human vaccines market. International cooperations and partnerships seek to offset restrictions in the accessibility of vaccines, reaching further into preventive immunization. Infectious diseases and the subsequent emergence of new pathogens impact vaccine demand. The emergence of novel infectious threats, or the return to vaccine preventable diseases results in research and development endeavour that would formulate effective vaccines against increasing challenges. Vaccine research and development is effectively fueled by significant governmental funding and support. Public-private partnerships and government risk sharing mechanisms help vaccine manufacturers receive financial incentives, which in turn leads to development of new innovative vaccines as well as timely introduction of such innovations into the market. Increased interest in the benefits of vaccination and public health education initiatives promote greater acceptance by people. Education on the prospect of immunization to prevent infectious diseases promote uptake and improve market demand. There is also increased vulnerability to infections among older adults due to the aging global population and increasing prevalence of chronic diseases The demand of vaccines used on this age group such as influenza and pneumonia vaccine witnesses growth due to which the market expands. The widespread use of vaccines in travel medicine, founded on the growing popularity of global traveling, contributes to market development.

Human Vaccines Market Size Graph
Author
Rahul Gotadki
Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch

Leave a Comment

FAQs

What is the current valuation of the Human Vaccines Market as of 2024?

<p>The Human Vaccines Market was valued at 666.04 USD Million in 2024.</p>

What is the projected market valuation for the Human Vaccines Market in 2035?

<p>The market is projected to reach a valuation of 1228.11 USD Million by 2035.</p>

What is the expected CAGR for the Human Vaccines Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Human Vaccines Market during the forecast period 2025 - 2035 is 5.72%.</p>

Which companies are considered key players in the Human Vaccines Market?

<p>Key players in the market include Pfizer, Moderna, Johnson & Johnson, Sanofi, GlaxoSmithKline, Merck & Co., AstraZeneca, Novartis, and Bayer.</p>

What are the main segments of the Human Vaccines Market by application?

<p>The main segments by application include Preventive Vaccines, Therapeutic Vaccines, Travel Vaccines, and Pediatric Vaccines.</p>

How do the valuations of Preventive and Therapeutic Vaccines compare?

<p>Preventive Vaccines are valued between 300.0 and 600.0 USD Million, whereas Therapeutic Vaccines are valued between 150.0 and 300.0 USD Million.</p>

What types of vaccines are included in the Human Vaccines Market?

<p>The market includes Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, and mRNA Vaccines.</p>

What is the valuation range for mRNA Vaccines in the market?

<p>mRNA Vaccines are valued between 216.04 and 328.11 USD Million.</p>

Which routes of administration are prevalent in the Human Vaccines Market?

<p>The prevalent routes of administration include Intramuscular, Subcutaneous, Oral, and Intranasal.</p>

What are the target diseases addressed by the Human Vaccines Market?

<p>The market addresses Viral Infections, Bacterial Infections, Parasitic Infections, and Cancer.</p>

Market Summary

As per MRFR analysis, the Human Vaccines Market Size was estimated at 666.04 USD Million in 2024. The Human Vaccines industry is projected to grow from 704.14 in 2025 to 1228.11 by 2035, exhibiting a compound annual growth rate (CAGR) of 5.72% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Human Vaccines Market is experiencing robust growth driven by technological advancements and increasing health awareness.

  • Advancements in vaccine technology are reshaping the landscape of immunization strategies.
  • North America remains the largest market, while Asia-Pacific is emerging as the fastest-growing region in the sector.
  • Preventive vaccines dominate the market, whereas therapeutic vaccines are witnessing rapid growth.
  • Rising incidence of infectious diseases and government initiatives are key drivers propelling market expansion.

Market Size & Forecast

2024 Market Size 666.04 (USD Million)
2035 Market Size 1228.11 (USD Million)
CAGR (2025 - 2035) 5.72%
Largest Regional Market Share in 2024 North America

Major Players

Pfizer (US), Moderna (US), Johnson & Johnson (US), Sanofi (FR), GlaxoSmithKline (GB), Merck & Co. (US), AstraZeneca (GB), Novartis (CH), Bayer (DE)

Market Trends

The Human Vaccines Market is currently experiencing a dynamic evolution, driven by various factors that influence both supply and demand. The increasing awareness of vaccine-preventable diseases, coupled with advancements in biotechnology, appears to be propelling the development of novel vaccines. Furthermore, the global emphasis on public health initiatives and immunization programs suggests a growing commitment to enhancing vaccine accessibility and distribution. This trend is likely to foster collaboration among governments, healthcare organizations, and pharmaceutical companies, thereby creating a more integrated approach to vaccine development and delivery. In addition, the Human Vaccines Market is witnessing a shift towards personalized medicine, where vaccines are tailored to individual genetic profiles. This approach may enhance vaccine efficacy and safety, potentially leading to higher acceptance rates among populations. Moreover, the rise of digital health technologies, including telemedicine and mobile health applications, indicates a transformation in how vaccination information is disseminated and how individuals engage with healthcare providers. As these trends continue to unfold, the Human Vaccines Market is poised for substantial growth, reflecting a broader commitment to global health and disease prevention.

Advancements in Vaccine Technology

The Human Vaccines Market is seeing significant innovations in vaccine technology, including mRNA and viral vector platforms. These advancements may lead to more effective and faster vaccine development processes, enhancing the ability to respond to emerging infectious diseases.

Increased Focus on Preventive Healthcare

There is a growing emphasis on preventive healthcare, which is likely to drive demand for vaccines. Public health campaigns and educational initiatives appear to be raising awareness about the importance of vaccination, potentially leading to higher immunization rates.

Integration of Digital Health Solutions

The integration of digital health solutions into the Human Vaccines Market is becoming more pronounced. Technologies such as mobile applications and telehealth services may facilitate better patient engagement and streamline vaccination processes, improving overall healthcare delivery.

Human Vaccines Market Market Drivers

Increasing Global Vaccination Coverage

The Global Human Vaccines Market Industry is experiencing growth due to the increasing emphasis on vaccination coverage across various populations. Governments worldwide are implementing policies aimed at enhancing immunization rates, particularly in developing regions. For instance, initiatives by the World Health Organization focus on achieving universal vaccination coverage, which is projected to significantly impact market dynamics. As of 2024, the market is valued at approximately 48.2 USD Billion, reflecting the importance of vaccination in public health strategies. This trend is expected to continue, with a projected market value of 78.5 USD Billion by 2035, indicating a sustained commitment to improving global health outcomes.

Market Segment Insights

By Application: Preventive Vaccines (Largest) vs. Therapeutic Vaccines (Fastest-Growing)

The Human Vaccines Market is predominantly led by Preventive Vaccines, which account for a significant share due to their extensive application in eradicating infectious diseases. These vaccines are crucial for public health initiatives and have widespread acceptance, thereby dominating market distribution. Therapeutic Vaccines, while smaller in market share, are witnessing rapid growth as they focus on treating existing health conditions, such as cancers and autoimmune diseases, which expands their relevance in the healthcare sector.

Preventive Vaccines (Dominant) vs. Therapeutic Vaccines (Emerging)

Preventive Vaccines represent the cornerstone of the Human Vaccines Market, characterized by their focus on prevention through immunization against infectious diseases. Their established nature and strong public health mandates make them the most significant segment. On the other hand, Therapeutic Vaccines are emerging as a transformative segment, aimed at treating diseases rather than preventing them. With advancements in biopharmaceuticals, these vaccines are gaining traction, particularly in cancer therapy. This diversification allows for a broader range of treatment options, thereby boosting interest and investment in research and development within this dynamic field.

By Type: Live Attenuated Vaccines (Largest) vs. mRNA Vaccines (Fastest-Growing)

<p>The human vaccines market is currently dominated by live attenuated vaccines, which hold the largest share due to their proven efficacy and long-term immunity benefits. Inactivated vaccines also have a significant presence, but live attenuated vaccines surpass them in market penetration. Subunit vaccines, while effective, occupy a smaller slice of the market, as do mRNA vaccines, which are gaining traction due to their groundbreaking approach to infection prevention.</p>

<p>Live Attenuated Vaccines (Dominant) vs. mRNA Vaccines (Emerging)</p>

<p>Live attenuated vaccines represent a traditional yet powerful category, often delivering robust immune responses through weakened forms of pathogens. Their efficacy in long-lasting immunity makes them the go-to choice for diseases like measles and mumps. In contrast, mRNA vaccines, although newer, are rapidly becoming a significant player; their quick development and adaptability have positioned them at the forefront, especially highlighted during global health crises like the COVID-19 pandemic. As research continues, the versatility and rapid production timeline of mRNA vaccines indicate their potential for future dominance in the market.</p>

By Route of Administration: Intramuscular (Largest) vs. Subcutaneous (Fastest-Growing)

The Human Vaccines Market exhibits a diverse distribution across the various routes of administration. Intramuscular vaccinations continue to hold the largest share in the market due to their effectiveness and widespread acceptance among healthcare providers. Subcutaneous administration is also significant, yet its growing adoption highlights a notable trend in the market. Oral and intranasal routes are less common but are gradually gaining traction in specific vaccine applications, catering to patient preferences and enhancing compliance.

Intramuscular (Dominant) vs. Subcutaneous (Emerging)

Intramuscular administration of vaccines remains the dominant method in the Human Vaccines Market, known for its robust immune response and reliable delivery mechanisms. This route allows for deeper tissue penetration, which is crucial for vaccines that require strong systemic effects. In contrast, subcutaneous administration is emerging as a key player due to its advantages in patient comfort and potential for self-administration, appealing to populations that prioritize ease and accessibility. As innovations in formulations and devices continue, subcutaneous vaccines are expected to occupy a more substantial market share, particularly in pediatric and adult immunization campaigns.

By Target Disease: Viral Infections (Largest) vs. Cancer (Fastest-Growing)

In the Human Vaccines Market, the segment distribution reveals viral infections as the dominant shareholder, primarily due to the high prevalence of diseases like influenza and hepatitis. Bacterial infections also hold a significant portion, with vaccines for diseases such as pneumococcal and meningococcal contributing to the market’s stability. Parasitic infections, although critical, represent a smaller fraction, while cancer vaccines are gaining traction, reflecting a dynamic shift in focus towards immunotherapeutic strategies.

Viral Infections (Dominant) vs. Cancer (Emerging)

Viral infections dominate the Human Vaccines Market largely because they address widespread and challenging infectious diseases like influenza and HPV. Established vaccines in this category maintain a strong market position due to continuous immunization programs and public health initiatives. Conversely, cancer vaccines are emerging strongly, driven by advancements in biotechnology and personalized medicine. This segment is characterized by innovative therapies that harness the immune system to combat various cancers, indicating a shift towards prophylactic and therapeutic vaccines. As research and development intensify in the oncology sector, the popularity and market share of cancer vaccines are expected to see exponential growth.

By End User: Hospitals (Largest) vs. Clinics (Fastest-Growing)

In the Human Vaccines Market, the distribution of market share among end users reveals Hospitals as the leading segment. They account for a significant portion of vaccine administration due to their established infrastructure and access to a large patient base. Clinics follow as a crucial segment, experiencing rapid growth as they shift toward more personalized care approaches. The convenience and accessibility offered by clinics are enhancing their role in the vaccination ecosystem, making them integral to future market dynamics.

Hospitals (Dominant) vs. Clinics (Emerging)

Hospitals represent the dominant end user segment in the Human Vaccines Market, primarily due to their comprehensive healthcare services and capacity to handle large patient volumes, particularly in urban areas. They are equipped with extensive facilities for vaccination, including specialized staff and technology, which helps in efficient vaccine distribution. On the other hand, Clinics are emerging as vital contributors to the market. They are adapting swiftly to changing healthcare demands, focusing on patient-centric approaches and community outreach. Their growth is driven by increased public awareness of vaccination benefits and a greater emphasis on preventive healthcare within local communities.

Get more detailed insights about Human Vaccines Market Research Report - Forecast to 2035

Regional Insights

North America : Market Leader in Vaccines

North America continues to lead the Human Vaccines Market, holding a significant share of 400.0M in 2024. The region's growth is driven by advanced healthcare infrastructure, high R&D investments, and a robust regulatory framework that supports vaccine development and distribution. Increasing vaccination rates and public health initiatives further bolster demand, ensuring a steady market expansion. The competitive landscape is characterized by major players such as Pfizer, Moderna, and Johnson & Johnson, which dominate the market with innovative vaccine solutions. The U.S. remains the largest contributor, supported by favorable government policies and funding for vaccine research. This environment fosters collaboration between public and private sectors, enhancing the region's position as a global leader in vaccine production and distribution.

Europe : Emerging Vaccine Innovation Hub

Europe's Human Vaccines Market is projected to reach 180.0M by 2025, driven by increasing healthcare investments and a strong focus on vaccine innovation. Regulatory bodies like the European Medicines Agency (EMA) play a crucial role in facilitating the approval of new vaccines, ensuring safety and efficacy. The region's commitment to public health initiatives and vaccination campaigns further enhances market demand, particularly in response to emerging infectious diseases. Leading countries such as Germany, France, and the UK are at the forefront of vaccine development, hosting major pharmaceutical companies like Sanofi and GlaxoSmithKline. The competitive landscape is marked by collaborations between governments and private entities, fostering innovation and ensuring a diverse vaccine portfolio. As Europe continues to prioritize health security, the market is expected to grow steadily, supported by regulatory advancements and public health strategies.

Asia-Pacific : Rapidly Growing Vaccine Market

The Asia-Pacific region is witnessing a significant surge in the Human Vaccines Market, projected to reach 70.0M by 2025. This growth is fueled by increasing healthcare expenditures, rising awareness of vaccination benefits, and government initiatives aimed at improving public health. Countries are focusing on expanding their immunization programs, which is critical in combating infectious diseases and enhancing overall health outcomes. Key players in this region include major pharmaceutical companies like Merck & Co. and AstraZeneca, which are actively involved in vaccine development and distribution. Countries such as China and India are leading the charge, supported by favorable regulatory environments and growing investments in healthcare infrastructure. The competitive landscape is evolving, with local manufacturers also emerging to meet the increasing demand for vaccines, ensuring a diverse market offering.

Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa (MEA) region is gradually developing its Human Vaccines Market, projected to reach 16.04M by 2025. The growth is driven by increasing healthcare investments and a rising awareness of vaccination importance. However, challenges such as limited access to healthcare and varying regulatory frameworks across countries can hinder market expansion. Governments are working to improve vaccination rates, which is essential for public health and disease prevention. Countries like South Africa and the UAE are leading the market, with efforts to enhance vaccine accessibility and affordability. The presence of key players such as Novartis and Bayer is crucial in addressing local health needs. Collaborative efforts between governments and international organizations are vital for overcoming barriers and ensuring that vaccines reach underserved populations, paving the way for a more robust market in the future.

Key Players and Competitive Insights

The Human Vaccines Market is characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and a focus on addressing emerging health threats. Key players such as Pfizer (US), Moderna (US), and Johnson & Johnson (US) are at the forefront, leveraging their extensive research capabilities and established market presence to enhance their operational focus. Pfizer (US) has been particularly aggressive in expanding its vaccine portfolio through collaborations and acquisitions, while Moderna (US) emphasizes mRNA technology to develop next-generation vaccines. Johnson & Johnson (US) continues to prioritize global access and affordability, which shapes its strategic positioning in various regions.The market structure appears moderately fragmented, with several players vying for market share. Key business tactics include localizing manufacturing to reduce costs and optimize supply chains, which is crucial in maintaining competitive pricing and ensuring timely delivery. The collective influence of these major companies fosters a competitive environment where innovation and operational efficiency are paramount.

In November Pfizer (US) announced a strategic partnership with a leading biotechnology firm to co-develop a novel vaccine targeting emerging viral strains. This collaboration is expected to enhance Pfizer's research capabilities and accelerate the development timeline, reflecting a broader trend of companies seeking synergies to bolster their R&D efforts. Such partnerships may significantly impact market dynamics by enabling faster responses to public health challenges.

In October Moderna (US) unveiled plans to expand its manufacturing facilities in Europe, aiming to increase production capacity for its mRNA vaccines. This move is strategically important as it positions Moderna to better serve the European market and respond to potential surges in vaccine demand. The expansion underscores the company's commitment to scaling operations and enhancing supply chain resilience, which is increasingly vital in the current market.

In September Johnson & Johnson (US) launched a new initiative focused on equitable vaccine distribution in low-income countries. This initiative not only aligns with global health goals but also enhances the company's reputation and market presence in regions where access to vaccines is limited. By prioritizing social responsibility, Johnson & Johnson is likely to strengthen its competitive edge and foster long-term loyalty among healthcare providers and governments.

As of December current trends in the Human Vaccines Market indicate a shift towards digitalization, sustainability, and the integration of AI technologies in vaccine development and distribution. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a greater emphasis on innovation and technology rather than solely on price. Companies that can reliably deliver high-quality vaccines while embracing sustainable practices are likely to emerge as leaders in this rapidly changing market.

Key Companies in the Human Vaccines Market include

Industry Developments

Recent developments in the Global Human Vaccines Market have been significantly influenced by various factors, including the ongoing response to infectious diseases and advancements in vaccine technology. In October 2023, Pfizer announced a collaboration with Moderna to enhance mRNA vaccine production efficiency, reflecting an industry trend toward partnerships for rapid vaccine development. Meanwhile, Merck and Co confirmed their investment in next-generation vaccine platforms to combat emerging pathogens, showcasing a commitment to innovation in vaccine efficacy and safety.

Currently, companies like Gilead Sciences and Johnson and Johnson are focusing on expanding their pipeline, especially in therapeutic vaccines targeting HIV and cancer, while Roche and Novartis are investing in biopharmaceuticals to enhance immunogenicity. Notably, GlaxoSmithKline has reported a substantial increase in vaccine sales, attributing this to rising vaccination rates globally.

In the past two to three years, the market has seen significant growth due to increased vaccination campaigns, particularly against COVID-19, with AstraZeneca and Sanofi making strides in vaccine distribution. The combined efforts of these leading firms illustrate a dynamic landscape in the Global Human Vaccines Market, emphasizing innovation and strategic collaborations to address public health challenges.

Future Outlook

Human Vaccines Market Future Outlook

The Human Vaccines Market is projected to grow at a 5.72% CAGR from 2025 to 2035, driven by technological advancements, increasing vaccination awareness, and expanding healthcare access.

New opportunities lie in:

  • Development of personalized vaccines targeting specific demographics.
  • Expansion of telehealth platforms for vaccine consultations.
  • Investment in cold chain logistics for vaccine distribution efficiency.

By 2035, the Human Vaccines Market is expected to be robust, driven by innovation and strategic investments.

Market Segmentation

Human Vaccines Market End User Outlook

  • Hospitals
  • Clinics
  • Pharmacies
  • Public Health Organizations

Human Vaccines Market Technology Outlook

  • Inactivated Vaccines
  • Live Attenuated Vaccines
  • Subunit Vaccines
  • mRNA Vaccines

Human Vaccines Market Application Outlook

  • Preventive Vaccines
  • Therapeutic Vaccines
  • Travel Vaccines
  • Pediatric Vaccines

Human Vaccines Market Target Disease Outlook

  • Viral Infections
  • Bacterial Infections
  • Parasitic Infections
  • Cancer

Human Vaccines Market Route of Administration Outlook

  • Intramuscular
  • Subcutaneous
  • Oral
  • Intranasal

Report Scope

MARKET SIZE 2024 666.04(USD Million)
MARKET SIZE 2025 704.14(USD Million)
MARKET SIZE 2035 1228.11(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 5.72% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Pfizer (US), Moderna (US), Johnson & Johnson (US), Sanofi (FR), GlaxoSmithKline (GB), Merck & Co. (US), AstraZeneca (GB), Novartis (CH), Bayer (DE)
Segments Covered Application, Technology, Route of Administration, Target Disease, End User
Key Market Opportunities Advancements in mRNA technology enhance vaccine development speed and efficacy in the Human Vaccines Market.
Key Market Dynamics Rising demand for innovative vaccines drives competitive forces and regulatory adaptations in the Human Vaccines Market.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the current valuation of the Human Vaccines Market as of 2024?

<p>The Human Vaccines Market was valued at 666.04 USD Million in 2024.</p>

What is the projected market valuation for the Human Vaccines Market in 2035?

<p>The market is projected to reach a valuation of 1228.11 USD Million by 2035.</p>

What is the expected CAGR for the Human Vaccines Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Human Vaccines Market during the forecast period 2025 - 2035 is 5.72%.</p>

Which companies are considered key players in the Human Vaccines Market?

<p>Key players in the market include Pfizer, Moderna, Johnson & Johnson, Sanofi, GlaxoSmithKline, Merck & Co., AstraZeneca, Novartis, and Bayer.</p>

What are the main segments of the Human Vaccines Market by application?

<p>The main segments by application include Preventive Vaccines, Therapeutic Vaccines, Travel Vaccines, and Pediatric Vaccines.</p>

How do the valuations of Preventive and Therapeutic Vaccines compare?

<p>Preventive Vaccines are valued between 300.0 and 600.0 USD Million, whereas Therapeutic Vaccines are valued between 150.0 and 300.0 USD Million.</p>

What types of vaccines are included in the Human Vaccines Market?

<p>The market includes Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, and mRNA Vaccines.</p>

What is the valuation range for mRNA Vaccines in the market?

<p>mRNA Vaccines are valued between 216.04 and 328.11 USD Million.</p>

Which routes of administration are prevalent in the Human Vaccines Market?

<p>The prevalent routes of administration include Intramuscular, Subcutaneous, Oral, and Intranasal.</p>

What are the target diseases addressed by the Human Vaccines Market?

<p>The market addresses Viral Infections, Bacterial Infections, Parasitic Infections, and Cancer.</p>

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
    2. | | 1.1.1 Market Overview
    3. | | 1.1.2 Key Findings
    4. | | 1.1.3 Market Segmentation
    5. | | 1.1.4 Competitive Landscape
    6. | | 1.1.5 Challenges and Opportunities
    7. | | 1.1.6 Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | | 2.1.1 Definition
    3. | | 2.1.2 Scope of the study
    4. | | | 2.1.2.1 Research Objective
    5. | | | 2.1.2.2 Assumption
    6. | | | 2.1.2.3 Limitations
    7. | 2.2 RESEARCH METHODOLOGY
    8. | | 2.2.1 Overview
    9. | | 2.2.2 Data Mining
    10. | | 2.2.3 Secondary Research
    11. | | 2.2.4 Primary Research
    12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
    13. | | | 2.2.4.2 Breakdown of Primary Respondents
    14. | | 2.2.5 Forecasting Model
    15. | | 2.2.6 Market Size Estimation
    16. | | | 2.2.6.1 Bottom-Up Approach
    17. | | | 2.2.6.2 Top-Down Approach
    18. | | 2.2.7 Data Triangulation
    19. | | 2.2.8 Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | | 3.1.1 Overview
    3. | | 3.1.2 Drivers
    4. | | 3.1.3 Restraints
    5. | | 3.1.4 Opportunities
    6. | 3.2 MARKET FACTOR ANALYSIS
    7. | | 3.2.1 Value chain Analysis
    8. | | 3.2.2 Porter's Five Forces Analysis
    9. | | | 3.2.2.1 Bargaining Power of Suppliers
    10. | | | 3.2.2.2 Bargaining Power of Buyers
    11. | | | 3.2.2.3 Threat of New Entrants
    12. | | | 3.2.2.4 Threat of Substitutes
    13. | | | 3.2.2.5 Intensity of Rivalry
    14. | | 3.2.3 COVID-19 Impact Analysis
    15. | | | 3.2.3.1 Market Impact Analysis
    16. | | | 3.2.3.2 Regional Impact
    17. | | | 3.2.3.3 Opportunity and Threat Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY Application (USD Million)
    2. | | 4.1.1 Preventive Vaccines
    3. | | 4.1.2 Therapeutic Vaccines
    4. | | 4.1.3 Travel Vaccines
    5. | | 4.1.4 Pediatric Vaccines
    6. | 4.2 Healthcare, BY Type (USD Million)
    7. | | 4.2.1 Live Attenuated Vaccines
    8. | | 4.2.2 Inactivated Vaccines
    9. | | 4.2.3 Subunit Vaccines
    10. | | 4.2.4 mRNA Vaccines
    11. | 4.3 Healthcare, BY Route of Administration (USD Million)
    12. | | 4.3.1 Intramuscular
    13. | | 4.3.2 Subcutaneous
    14. | | 4.3.3 Oral
    15. | | 4.3.4 Intranasal
    16. | 4.4 Healthcare, BY Target Disease (USD Million)
    17. | | 4.4.1 Viral Infections
    18. | | 4.4.2 Bacterial Infections
    19. | | 4.4.3 Parasitic Infections
    20. | | 4.4.4 Cancer
    21. | 4.5 Healthcare, BY End User (USD Million)
    22. | | 4.5.1 Hospitals
    23. | | 4.5.2 Clinics
    24. | | 4.5.3 Pharmacies
    25. | | 4.5.4 Research Institutions
    26. | 4.6 Healthcare, BY Region (USD Million)
    27. | | 4.6.1 North America
    28. | | | 4.6.1.1 US
    29. | | | 4.6.1.2 Canada
    30. | | 4.6.2 Europe
    31. | | | 4.6.2.1 Germany
    32. | | | 4.6.2.2 UK
    33. | | | 4.6.2.3 France
    34. | | | 4.6.2.4 Russia
    35. | | | 4.6.2.5 Italy
    36. | | | 4.6.2.6 Spain
    37. | | | 4.6.2.7 Rest of Europe
    38. | | 4.6.3 APAC
    39. | | | 4.6.3.1 China
    40. | | | 4.6.3.2 India
    41. | | | 4.6.3.3 Japan
    42. | | | 4.6.3.4 South Korea
    43. | | | 4.6.3.5 Malaysia
    44. | | | 4.6.3.6 Thailand
    45. | | | 4.6.3.7 Indonesia
    46. | | | 4.6.3.8 Rest of APAC
    47. | | 4.6.4 South America
    48. | | | 4.6.4.1 Brazil
    49. | | | 4.6.4.2 Mexico
    50. | | | 4.6.4.3 Argentina
    51. | | | 4.6.4.4 Rest of South America
    52. | | 4.6.5 MEA
    53. | | | 4.6.5.1 GCC Countries
    54. | | | 4.6.5.2 South Africa
    55. | | | 4.6.5.3 Rest of MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | | 5.1.1 Overview
    3. | | 5.1.2 Competitive Analysis
    4. | | 5.1.3 Market share Analysis
    5. | | 5.1.4 Major Growth Strategy in the Healthcare
    6. | | 5.1.5 Competitive Benchmarking
    7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
    8. | | 5.1.7 Key developments and growth strategies
    9. | | | 5.1.7.1 New Product Launch/Service Deployment
    10. | | | 5.1.7.2 Merger & Acquisitions
    11. | | | 5.1.7.3 Joint Ventures
    12. | | 5.1.8 Major Players Financial Matrix
    13. | | | 5.1.8.1 Sales and Operating Income
    14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
    15. | 5.2 Company Profiles
    16. | | 5.2.1 Pfizer (US)
    17. | | | 5.2.1.1 Financial Overview
    18. | | | 5.2.1.2 Products Offered
    19. | | | 5.2.1.3 Key Developments
    20. | | | 5.2.1.4 SWOT Analysis
    21. | | | 5.2.1.5 Key Strategies
    22. | | 5.2.2 Moderna (US)
    23. | | | 5.2.2.1 Financial Overview
    24. | | | 5.2.2.2 Products Offered
    25. | | | 5.2.2.3 Key Developments
    26. | | | 5.2.2.4 SWOT Analysis
    27. | | | 5.2.2.5 Key Strategies
    28. | | 5.2.3 Johnson & Johnson (US)
    29. | | | 5.2.3.1 Financial Overview
    30. | | | 5.2.3.2 Products Offered
    31. | | | 5.2.3.3 Key Developments
    32. | | | 5.2.3.4 SWOT Analysis
    33. | | | 5.2.3.5 Key Strategies
    34. | | 5.2.4 Sanofi (FR)
    35. | | | 5.2.4.1 Financial Overview
    36. | | | 5.2.4.2 Products Offered
    37. | | | 5.2.4.3 Key Developments
    38. | | | 5.2.4.4 SWOT Analysis
    39. | | | 5.2.4.5 Key Strategies
    40. | | 5.2.5 GlaxoSmithKline (GB)
    41. | | | 5.2.5.1 Financial Overview
    42. | | | 5.2.5.2 Products Offered
    43. | | | 5.2.5.3 Key Developments
    44. | | | 5.2.5.4 SWOT Analysis
    45. | | | 5.2.5.5 Key Strategies
    46. | | 5.2.6 Merck & Co. (US)
    47. | | | 5.2.6.1 Financial Overview
    48. | | | 5.2.6.2 Products Offered
    49. | | | 5.2.6.3 Key Developments
    50. | | | 5.2.6.4 SWOT Analysis
    51. | | | 5.2.6.5 Key Strategies
    52. | | 5.2.7 AstraZeneca (GB)
    53. | | | 5.2.7.1 Financial Overview
    54. | | | 5.2.7.2 Products Offered
    55. | | | 5.2.7.3 Key Developments
    56. | | | 5.2.7.4 SWOT Analysis
    57. | | | 5.2.7.5 Key Strategies
    58. | | 5.2.8 Novartis (CH)
    59. | | | 5.2.8.1 Financial Overview
    60. | | | 5.2.8.2 Products Offered
    61. | | | 5.2.8.3 Key Developments
    62. | | | 5.2.8.4 SWOT Analysis
    63. | | | 5.2.8.5 Key Strategies
    64. | | 5.2.9 Bayer (DE)
    65. | | | 5.2.9.1 Financial Overview
    66. | | | 5.2.9.2 Products Offered
    67. | | | 5.2.9.3 Key Developments
    68. | | | 5.2.9.4 SWOT Analysis
    69. | | | 5.2.9.5 Key Strategies
    70. | 5.3 Appendix
    71. | | 5.3.1 References
    72. | | 5.3.2 Related Reports
  6. LIST OF FIGURES
    1. | 6.1 MARKET SYNOPSIS
    2. | 6.2 NORTH AMERICA MARKET ANALYSIS
    3. | 6.3 US MARKET ANALYSIS BY APPLICATION
    4. | 6.4 US MARKET ANALYSIS BY TYPE
    5. | 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    6. | 6.6 US MARKET ANALYSIS BY TARGET DISEASE
    7. | 6.7 US MARKET ANALYSIS BY END USER
    8. | 6.8 CANADA MARKET ANALYSIS BY APPLICATION
    9. | 6.9 CANADA MARKET ANALYSIS BY TYPE
    10. | 6.10 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    11. | 6.11 CANADA MARKET ANALYSIS BY TARGET DISEASE
    12. | 6.12 CANADA MARKET ANALYSIS BY END USER
    13. | 6.13 EUROPE MARKET ANALYSIS
    14. | 6.14 GERMANY MARKET ANALYSIS BY APPLICATION
    15. | 6.15 GERMANY MARKET ANALYSIS BY TYPE
    16. | 6.16 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    17. | 6.17 GERMANY MARKET ANALYSIS BY TARGET DISEASE
    18. | 6.18 GERMANY MARKET ANALYSIS BY END USER
    19. | 6.19 UK MARKET ANALYSIS BY APPLICATION
    20. | 6.20 UK MARKET ANALYSIS BY TYPE
    21. | 6.21 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    22. | 6.22 UK MARKET ANALYSIS BY TARGET DISEASE
    23. | 6.23 UK MARKET ANALYSIS BY END USER
    24. | 6.24 FRANCE MARKET ANALYSIS BY APPLICATION
    25. | 6.25 FRANCE MARKET ANALYSIS BY TYPE
    26. | 6.26 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    27. | 6.27 FRANCE MARKET ANALYSIS BY TARGET DISEASE
    28. | 6.28 FRANCE MARKET ANALYSIS BY END USER
    29. | 6.29 RUSSIA MARKET ANALYSIS BY APPLICATION
    30. | 6.30 RUSSIA MARKET ANALYSIS BY TYPE
    31. | 6.31 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    32. | 6.32 RUSSIA MARKET ANALYSIS BY TARGET DISEASE
    33. | 6.33 RUSSIA MARKET ANALYSIS BY END USER
    34. | 6.34 ITALY MARKET ANALYSIS BY APPLICATION
    35. | 6.35 ITALY MARKET ANALYSIS BY TYPE
    36. | 6.36 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    37. | 6.37 ITALY MARKET ANALYSIS BY TARGET DISEASE
    38. | 6.38 ITALY MARKET ANALYSIS BY END USER
    39. | 6.39 SPAIN MARKET ANALYSIS BY APPLICATION
    40. | 6.40 SPAIN MARKET ANALYSIS BY TYPE
    41. | 6.41 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    42. | 6.42 SPAIN MARKET ANALYSIS BY TARGET DISEASE
    43. | 6.43 SPAIN MARKET ANALYSIS BY END USER
    44. | 6.44 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
    45. | 6.45 REST OF EUROPE MARKET ANALYSIS BY TYPE
    46. | 6.46 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    47. | 6.47 REST OF EUROPE MARKET ANALYSIS BY TARGET DISEASE
    48. | 6.48 REST OF EUROPE MARKET ANALYSIS BY END USER
    49. | 6.49 APAC MARKET ANALYSIS
    50. | 6.50 CHINA MARKET ANALYSIS BY APPLICATION
    51. | 6.51 CHINA MARKET ANALYSIS BY TYPE
    52. | 6.52 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    53. | 6.53 CHINA MARKET ANALYSIS BY TARGET DISEASE
    54. | 6.54 CHINA MARKET ANALYSIS BY END USER
    55. | 6.55 INDIA MARKET ANALYSIS BY APPLICATION
    56. | 6.56 INDIA MARKET ANALYSIS BY TYPE
    57. | 6.57 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    58. | 6.58 INDIA MARKET ANALYSIS BY TARGET DISEASE
    59. | 6.59 INDIA MARKET ANALYSIS BY END USER
    60. | 6.60 JAPAN MARKET ANALYSIS BY APPLICATION
    61. | 6.61 JAPAN MARKET ANALYSIS BY TYPE
    62. | 6.62 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    63. | 6.63 JAPAN MARKET ANALYSIS BY TARGET DISEASE
    64. | 6.64 JAPAN MARKET ANALYSIS BY END USER
    65. | 6.65 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
    66. | 6.66 SOUTH KOREA MARKET ANALYSIS BY TYPE
    67. | 6.67 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    68. | 6.68 SOUTH KOREA MARKET ANALYSIS BY TARGET DISEASE
    69. | 6.69 SOUTH KOREA MARKET ANALYSIS BY END USER
    70. | 6.70 MALAYSIA MARKET ANALYSIS BY APPLICATION
    71. | 6.71 MALAYSIA MARKET ANALYSIS BY TYPE
    72. | 6.72 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    73. | 6.73 MALAYSIA MARKET ANALYSIS BY TARGET DISEASE
    74. | 6.74 MALAYSIA MARKET ANALYSIS BY END USER
    75. | 6.75 THAILAND MARKET ANALYSIS BY APPLICATION
    76. | 6.76 THAILAND MARKET ANALYSIS BY TYPE
    77. | 6.77 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    78. | 6.78 THAILAND MARKET ANALYSIS BY TARGET DISEASE
    79. | 6.79 THAILAND MARKET ANALYSIS BY END USER
    80. | 6.80 INDONESIA MARKET ANALYSIS BY APPLICATION
    81. | 6.81 INDONESIA MARKET ANALYSIS BY TYPE
    82. | 6.82 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    83. | 6.83 INDONESIA MARKET ANALYSIS BY TARGET DISEASE
    84. | 6.84 INDONESIA MARKET ANALYSIS BY END USER
    85. | 6.85 REST OF APAC MARKET ANALYSIS BY APPLICATION
    86. | 6.86 REST OF APAC MARKET ANALYSIS BY TYPE
    87. | 6.87 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    88. | 6.88 REST OF APAC MARKET ANALYSIS BY TARGET DISEASE
    89. | 6.89 REST OF APAC MARKET ANALYSIS BY END USER
    90. | 6.90 SOUTH AMERICA MARKET ANALYSIS
    91. | 6.91 BRAZIL MARKET ANALYSIS BY APPLICATION
    92. | 6.92 BRAZIL MARKET ANALYSIS BY TYPE
    93. | 6.93 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    94. | 6.94 BRAZIL MARKET ANALYSIS BY TARGET DISEASE
    95. | 6.95 BRAZIL MARKET ANALYSIS BY END USER
    96. | 6.96 MEXICO MARKET ANALYSIS BY APPLICATION
    97. | 6.97 MEXICO MARKET ANALYSIS BY TYPE
    98. | 6.98 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    99. | 6.99 MEXICO MARKET ANALYSIS BY TARGET DISEASE
    100. | 6.100 MEXICO MARKET ANALYSIS BY END USER
    101. | 6.101 ARGENTINA MARKET ANALYSIS BY APPLICATION
    102. | 6.102 ARGENTINA MARKET ANALYSIS BY TYPE
    103. | 6.103 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    104. | 6.104 ARGENTINA MARKET ANALYSIS BY TARGET DISEASE
    105. | 6.105 ARGENTINA MARKET ANALYSIS BY END USER
    106. | 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
    107. | 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
    108. | 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    109. | 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY TARGET DISEASE
    110. | 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
    111. | 6.111 MEA MARKET ANALYSIS
    112. | 6.112 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
    113. | 6.113 GCC COUNTRIES MARKET ANALYSIS BY TYPE
    114. | 6.114 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    115. | 6.115 GCC COUNTRIES MARKET ANALYSIS BY TARGET DISEASE
    116. | 6.116 GCC COUNTRIES MARKET ANALYSIS BY END USER
    117. | 6.117 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
    118. | 6.118 SOUTH AFRICA MARKET ANALYSIS BY TYPE
    119. | 6.119 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    120. | 6.120 SOUTH AFRICA MARKET ANALYSIS BY TARGET DISEASE
    121. | 6.121 SOUTH AFRICA MARKET ANALYSIS BY END USER
    122. | 6.122 REST OF MEA MARKET ANALYSIS BY APPLICATION
    123. | 6.123 REST OF MEA MARKET ANALYSIS BY TYPE
    124. | 6.124 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    125. | 6.125 REST OF MEA MARKET ANALYSIS BY TARGET DISEASE
    126. | 6.126 REST OF MEA MARKET ANALYSIS BY END USER
    127. | 6.127 KEY BUYING CRITERIA OF HEALTHCARE
    128. | 6.128 RESEARCH PROCESS OF MRFR
    129. | 6.129 DRO ANALYSIS OF HEALTHCARE
    130. | 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    131. | 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    132. | 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
    133. | 6.133 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    134. | 6.134 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
    135. | 6.135 HEALTHCARE, BY TYPE, 2024 (% SHARE)
    136. | 6.136 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Million)
    137. | 6.137 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    138. | 6.138 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
    139. | 6.139 HEALTHCARE, BY TARGET DISEASE, 2024 (% SHARE)
    140. | 6.140 HEALTHCARE, BY TARGET DISEASE, 2024 TO 2035 (USD Million)
    141. | 6.141 HEALTHCARE, BY END USER, 2024 (% SHARE)
    142. | 6.142 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Million)
    143. | 6.143 BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. | 7.1 LIST OF ASSUMPTIONS
    2. | | 7.1.1
    3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
    4. | | 7.2.1 BY APPLICATION, 2025-2035 (USD Million)
    5. | | 7.2.2 BY TYPE, 2025-2035 (USD Million)
    6. | | 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    7. | | 7.2.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    8. | | 7.2.5 BY END USER, 2025-2035 (USD Million)
    9. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
    10. | | 7.3.1 BY APPLICATION, 2025-2035 (USD Million)
    11. | | 7.3.2 BY TYPE, 2025-2035 (USD Million)
    12. | | 7.3.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    13. | | 7.3.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    14. | | 7.3.5 BY END USER, 2025-2035 (USD Million)
    15. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
    16. | | 7.4.1 BY APPLICATION, 2025-2035 (USD Million)
    17. | | 7.4.2 BY TYPE, 2025-2035 (USD Million)
    18. | | 7.4.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    19. | | 7.4.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    20. | | 7.4.5 BY END USER, 2025-2035 (USD Million)
    21. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
    22. | | 7.5.1 BY APPLICATION, 2025-2035 (USD Million)
    23. | | 7.5.2 BY TYPE, 2025-2035 (USD Million)
    24. | | 7.5.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    25. | | 7.5.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    26. | | 7.5.5 BY END USER, 2025-2035 (USD Million)
    27. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
    28. | | 7.6.1 BY APPLICATION, 2025-2035 (USD Million)
    29. | | 7.6.2 BY TYPE, 2025-2035 (USD Million)
    30. | | 7.6.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    31. | | 7.6.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    32. | | 7.6.5 BY END USER, 2025-2035 (USD Million)
    33. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
    34. | | 7.7.1 BY APPLICATION, 2025-2035 (USD Million)
    35. | | 7.7.2 BY TYPE, 2025-2035 (USD Million)
    36. | | 7.7.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    37. | | 7.7.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    38. | | 7.7.5 BY END USER, 2025-2035 (USD Million)
    39. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
    40. | | 7.8.1 BY APPLICATION, 2025-2035 (USD Million)
    41. | | 7.8.2 BY TYPE, 2025-2035 (USD Million)
    42. | | 7.8.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    43. | | 7.8.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    44. | | 7.8.5 BY END USER, 2025-2035 (USD Million)
    45. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
    46. | | 7.9.1 BY APPLICATION, 2025-2035 (USD Million)
    47. | | 7.9.2 BY TYPE, 2025-2035 (USD Million)
    48. | | 7.9.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    49. | | 7.9.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    50. | | 7.9.5 BY END USER, 2025-2035 (USD Million)
    51. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
    52. | | 7.10.1 BY APPLICATION, 2025-2035 (USD Million)
    53. | | 7.10.2 BY TYPE, 2025-2035 (USD Million)
    54. | | 7.10.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    55. | | 7.10.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    56. | | 7.10.5 BY END USER, 2025-2035 (USD Million)
    57. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
    58. | | 7.11.1 BY APPLICATION, 2025-2035 (USD Million)
    59. | | 7.11.2 BY TYPE, 2025-2035 (USD Million)
    60. | | 7.11.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    61. | | 7.11.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    62. | | 7.11.5 BY END USER, 2025-2035 (USD Million)
    63. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
    64. | | 7.12.1 BY APPLICATION, 2025-2035 (USD Million)
    65. | | 7.12.2 BY TYPE, 2025-2035 (USD Million)
    66. | | 7.12.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    67. | | 7.12.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    68. | | 7.12.5 BY END USER, 2025-2035 (USD Million)
    69. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
    70. | | 7.13.1 BY APPLICATION, 2025-2035 (USD Million)
    71. | | 7.13.2 BY TYPE, 2025-2035 (USD Million)
    72. | | 7.13.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    73. | | 7.13.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    74. | | 7.13.5 BY END USER, 2025-2035 (USD Million)
    75. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
    76. | | 7.14.1 BY APPLICATION, 2025-2035 (USD Million)
    77. | | 7.14.2 BY TYPE, 2025-2035 (USD Million)
    78. | | 7.14.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    79. | | 7.14.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    80. | | 7.14.5 BY END USER, 2025-2035 (USD Million)
    81. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
    82. | | 7.15.1 BY APPLICATION, 2025-2035 (USD Million)
    83. | | 7.15.2 BY TYPE, 2025-2035 (USD Million)
    84. | | 7.15.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    85. | | 7.15.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    86. | | 7.15.5 BY END USER, 2025-2035 (USD Million)
    87. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
    88. | | 7.16.1 BY APPLICATION, 2025-2035 (USD Million)
    89. | | 7.16.2 BY TYPE, 2025-2035 (USD Million)
    90. | | 7.16.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    91. | | 7.16.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    92. | | 7.16.5 BY END USER, 2025-2035 (USD Million)
    93. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
    94. | | 7.17.1 BY APPLICATION, 2025-2035 (USD Million)
    95. | | 7.17.2 BY TYPE, 2025-2035 (USD Million)
    96. | | 7.17.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    97. | | 7.17.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    98. | | 7.17.5 BY END USER, 2025-2035 (USD Million)
    99. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
    100. | | 7.18.1 BY APPLICATION, 2025-2035 (USD Million)
    101. | | 7.18.2 BY TYPE, 2025-2035 (USD Million)
    102. | | 7.18.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    103. | | 7.18.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    104. | | 7.18.5 BY END USER, 2025-2035 (USD Million)
    105. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
    106. | | 7.19.1 BY APPLICATION, 2025-2035 (USD Million)
    107. | | 7.19.2 BY TYPE, 2025-2035 (USD Million)
    108. | | 7.19.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    109. | | 7.19.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    110. | | 7.19.5 BY END USER, 2025-2035 (USD Million)
    111. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
    112. | | 7.20.1 BY APPLICATION, 2025-2035 (USD Million)
    113. | | 7.20.2 BY TYPE, 2025-2035 (USD Million)
    114. | | 7.20.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    115. | | 7.20.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    116. | | 7.20.5 BY END USER, 2025-2035 (USD Million)
    117. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
    118. | | 7.21.1 BY APPLICATION, 2025-2035 (USD Million)
    119. | | 7.21.2 BY TYPE, 2025-2035 (USD Million)
    120. | | 7.21.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    121. | | 7.21.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    122. | | 7.21.5 BY END USER, 2025-2035 (USD Million)
    123. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
    124. | | 7.22.1 BY APPLICATION, 2025-2035 (USD Million)
    125. | | 7.22.2 BY TYPE, 2025-2035 (USD Million)
    126. | | 7.22.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    127. | | 7.22.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    128. | | 7.22.5 BY END USER, 2025-2035 (USD Million)
    129. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
    130. | | 7.23.1 BY APPLICATION, 2025-2035 (USD Million)
    131. | | 7.23.2 BY TYPE, 2025-2035 (USD Million)
    132. | | 7.23.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    133. | | 7.23.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    134. | | 7.23.5 BY END USER, 2025-2035 (USD Million)
    135. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
    136. | | 7.24.1 BY APPLICATION, 2025-2035 (USD Million)
    137. | | 7.24.2 BY TYPE, 2025-2035 (USD Million)
    138. | | 7.24.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    139. | | 7.24.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    140. | | 7.24.5 BY END USER, 2025-2035 (USD Million)
    141. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
    142. | | 7.25.1 BY APPLICATION, 2025-2035 (USD Million)
    143. | | 7.25.2 BY TYPE, 2025-2035 (USD Million)
    144. | | 7.25.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    145. | | 7.25.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    146. | | 7.25.5 BY END USER, 2025-2035 (USD Million)
    147. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
    148. | | 7.26.1 BY APPLICATION, 2025-2035 (USD Million)
    149. | | 7.26.2 BY TYPE, 2025-2035 (USD Million)
    150. | | 7.26.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    151. | | 7.26.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    152. | | 7.26.5 BY END USER, 2025-2035 (USD Million)
    153. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
    154. | | 7.27.1 BY APPLICATION, 2025-2035 (USD Million)
    155. | | 7.27.2 BY TYPE, 2025-2035 (USD Million)
    156. | | 7.27.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    157. | | 7.27.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    158. | | 7.27.5 BY END USER, 2025-2035 (USD Million)
    159. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
    160. | | 7.28.1 BY APPLICATION, 2025-2035 (USD Million)
    161. | | 7.28.2 BY TYPE, 2025-2035 (USD Million)
    162. | | 7.28.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    163. | | 7.28.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    164. | | 7.28.5 BY END USER, 2025-2035 (USD Million)
    165. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
    166. | | 7.29.1 BY APPLICATION, 2025-2035 (USD Million)
    167. | | 7.29.2 BY TYPE, 2025-2035 (USD Million)
    168. | | 7.29.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    169. | | 7.29.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    170. | | 7.29.5 BY END USER, 2025-2035 (USD Million)
    171. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
    172. | | 7.30.1 BY APPLICATION, 2025-2035 (USD Million)
    173. | | 7.30.2 BY TYPE, 2025-2035 (USD Million)
    174. | | 7.30.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
    175. | | 7.30.4 BY TARGET DISEASE, 2025-2035 (USD Million)
    176. | | 7.30.5 BY END USER, 2025-2035 (USD Million)
    177. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    178. | | 7.31.1
    179. | 7.32 ACQUISITION/PARTNERSHIP
    180. | | 7.32.1

Healthcare Market Segmentation

Healthcare By Application (USD Million, 2025-2035)

  • Preventive Vaccines
  • Therapeutic Vaccines
  • Travel Vaccines
  • Pediatric Vaccines

Healthcare By Type (USD Million, 2025-2035)

  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Subunit Vaccines
  • mRNA Vaccines

Healthcare By Route of Administration (USD Million, 2025-2035)

  • Intramuscular
  • Subcutaneous
  • Oral
  • Intranasal

Healthcare By Target Disease (USD Million, 2025-2035)

  • Viral Infections
  • Bacterial Infections
  • Parasitic Infections
  • Cancer

Healthcare By End User (USD Million, 2025-2035)

  • Hospitals
  • Clinics
  • Pharmacies
  • Research Institutions
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓